Retatrutide Injection

Retatrutide is an experimental drug for obesity. It is a triple glucagon hormone receptor agonist (GLP-1, GIP, and GCGR receptors). Retatrutide has been studied in a phase 2 trial involving adults without diabetes but with obesity or preobesity (overweight). Retatrutide is also being evaluated in phase 3 clinical trials. A substudy in adults with type 2 diabetes reported differences in total body fat mass between study groups at 36 weeks.

What are the Side Effects of Retatrutide?

Across clinical studies, the most commonly reported adverse events were gastrointestinal symptoms such as nausea, vomiting, and diarrhea.

Is Retatrutide available in India?

Retatrutide may be accessed in India through a named-patient import process with a valid doctor’s prescription, and Indian Pharma Network (IPN), New Delhi, assists with compliant sourcing and delivery of specialty medicines subject to regulatory approvals.

How to get Retatrutide injection delivered in India?

Indian Pharma Network (IPN), based in New Delhi, helps patients and healthcare providers with the sourcing and import coordination of specialty medicines in compliance with applicable Indian regulations. Availability, import eligibility, pricing, and delivery timelines may vary and are subject to regulatory approvals and documentation requirements.

IPN having representation in Delhi, Gurugram, Mumbai, Bengaluru, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur, and Lucknow.

Who can help source Retatrutide injection in India legally?

Named-patient import facilitator contact details
Company Name: Indian Pharma Network (IPN)
Address: 60/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016
For sourcing and import coordination of specialty medicines, contact:
Mr. Tarun: +91 9891 296 838
Mr. Neeraj: +91 9811 747 774
Email: info@indianpharmanetwork.co.in

Patients are advised to independently verify the credentials, licensing, and regulatory compliance of any facilitator before proceeding.

NEWS/UPDATES

• FDA approves therapy for rare blood disorder in pediatric patients 12 years and older.
• FDA approved caplacizumab-yhdp.
• FDA approves caplacizumab for pediatric acquired thrombotic thrombocytopenic purpura.
• FDA approves Sanofi’s Cablivi as first therapy for rare blood disorder.

Note:
We are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient. Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India. With over two decades of industry experience, IPN offers extensive coverage across India.